Novel Ruthenium - Gamma-linolenic acid complex inhibits C6 rat glioma cell proliferation In Vitro and in the orthotopic C6 model In Vivo after osmotic pump infusion

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1901-1912

  Miyake, Juliano Andreoli ^a   Benadiba, Marcel ^a   Ribeiro, Geise ^a   De Oliveira Silva, Denise ^a   Colquhoun, Alison ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gamma linolenic acid; Glioma; Proliferation; Ruthenium apoptosis

Indexed keywords

GAMMA LINOLENIC ACID; RUTHENIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; COLLAGEN FIBER; CONTROLLED STUDY; DNA REPLICATION; EXTRACELLULAR MATRIX; GLIOMA; GLIOMA CELL; IN VITRO STUDY; NONHUMAN; OSMOTIC PUMP; RAT; ANIMAL; APOPTOSIS; DISEASE MODEL; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; PROLIFERATION; TUMOR CELL LINE; TUMOR VOLUME; ULTRASTRUCTURE;

APOPTOSIS; GAMMA-LINOLENIC ACID; GLIOMA; PROLIFERATION; RUTHENIUM;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FEMALE; GAMMA-LINOLENIC ACID; GLIOMA; RATS; RUTHENIUM; TUMOR BURDEN;

EID: 84902126606     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Giese A, Bjerkvig R, Berens ME and Westphal M: Cost of migration: Invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624-1636, 2003.
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics and biology of a grave matter. Genes Dev 15: 1311-1333, 2001.
3. Ferguson S and Lesniak MS: Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv 4 (2): 169-180, 2007.
4. Wen PY, Kesari S and Drappatz J: Malignant gliomas: Strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther 6(5): 733-754, 2006.
5. Jiang H, Alonso MM, Gomez-Manzano C, Piao Y and Fueyo J: Oncolytic viruses and DNA-repair machinery: Overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 6(11): 1585-1592, 2006.
6. Kim L and Glantz M: Chemotherapeutic options for primary brain tumors. Curr Treat Options Oncol 7(6): 467-478, 2006.
7. Tuettenberg J, Friedel C and Vajkoczy P: Angiogenesis in malignant glioma - a target for antitumor therapy? Crit Rev Oncol Hematol 59(3): 181-193, 2006.
8. Begin ME, Ells G, Das UN and Horrobin DF: Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Natl Cancer Inst 7 (5): 1053-1062, 1996.
9. Das UN: Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukot Essent Fatty Acids 61(3): 157-613, 1999.
10. Naidu MR, Das UN and Kishan A: Intratumoral gammalinoleic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids 45(3): 181-184, 1992.
11. Das UN, Prasad VV and Reddy DR: Local application of gamma-linolenic acid in the treatment of human gliomas. Cancer Lett 94 (2): 147-155, 1995.
12. Leaver HA, Wharton SB, Bell HS, Leaver-Yap IM and Whittle IR: Highly unsaturated fatty acid induced tumour regression in glioma pharmacodynamics and bioavailability of gamma linolenic acid in an implantation glioma model: Effects on tumour biomass, apoptosis and neuronal tissue histology. Prostaglandins Leukot Essent Fatty Acids 67(5): 283-292, 2002.
13. Bakshi A, Mukherjee D, Bakshi A, Banerji AK and Das UN: Gamma-linolenic acid therapy of human gliomas. Nutrition 19(4): 305-309.
14. Comment 19(4): 386-388, 2003.
15. Leaver HA, Williams JR, Smith C and Whittle IR: Intracellular oxidation by human glioma cell populations: Effect of arachidonic acid. Prostaglandins Leukot Essent Fatty Acids 70(5): 449-453, 2004.
16. Das UN: From bench to the clinic: Gamma-linolenic acid therapy of human gliomas. Prostaglandins Leukot Essent Fatty Acids 70(6): 539-552, 2004.
17. Miyake JA, Benadiba M and Colquhoun A: Gamma-linolenic acid inhibits both tumour cell cycle progression and angiogenesis in the orthotopic C6 glioma model through changes in VEGF, FLT-1, ERK1/2, MMP2, cyclin D1, pRb, p53 and p27 protein expression. Lipids Health Dis 8: 8, 2009.
18. Colquhoun A and Schumacher RI: Gamma-linolenic acid and eicosapentaenoic acid induce modifications in mitochondrial metabolism, reactive oxygen species generation, lipid peroxidation and apoptosis in Walker 256 rat carcinosarcoma cells. Biochim Biophys Acta 1533(3): 207-219, 2001a.
19. Colquhoun A and Schumacher RI: Modifications in mitochondrial metabolism and ultrastructure and their relationship to tumour growth inhibition by gamma-linolenic acid. Mol Cell Biochem 218(1-2): 13-20, 2001b.
20. Colquhoun A: Gamma-linolenic acid alters the composition of mitochondrial membrane subfractions, decreases outer mitochondrial membrane binding of hexokinase and alters carnitine palmitoyltransferase I properties in the Walker 256 rat tumour. Biochim Biophys Acta 1583(1): 74-84, 2002.
21. Ramos KL and Colquhoun A: Protective role of glucose-6-phosphate dehydrogenase activity in the metabolic response of C6 rat glioma cells to polyunsaturated fatty acid exposure. Glia 43(2): 149-166, 2003.
22. Vartak S, Robbins ME and Spector AA: Polyunsaturated fatty acids increase the sensitivity of 36B10 rat astrocytoma cells to radiation-induced cell kill. Lipids 32(3): 283-292, 1997.
23. Vartak S, McCaw R, Davis CS, Robbins ME and Spector AA: Gamma-linolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to 'normal' rat astrocytes. Br J Cancer 77 (10): 1612-1620, 1998.
24. Wernyj RP and Morin PJ: Molecular mechanisms of platinum resistance: Still searching for the Achilles' heel. Drug Resist Updat 7(4-5): 227-232, 2004.
25. Brabec V and Novakova O: DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist Updat 9(3): 111-122, 2006.
26. 2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes. J Inorg Biochem 98 (12): 2168-2173, 2004.
27. Keppler BK, Lipponer K, Stenzel B and Kratz F: Metal Complexes in Cancer Chemotherapy. Keppler BK. First Edition. VCH: New York, 1993.
28. Andrade A, Namora SF, Woisky RG, Wiezel G, Najjar R, Sertié JAA and de Oliveira Silva D: Synthesis and characterization of a diruthenium-ibuprofenate complex comparing its anti-inflammatory activity with that of a copper(II)-ibuprofenate complex. J. Inorg. Biochem 81: 23-27, 2000.
29. Aquino MAS: Recent developments in the synthesis and properties of diruthenium tetracarboxylates Coord. Chem. Rev 248: 1025-1045, 2004.
30. Ribeiro G, Benadiba M, de Oliveira Silva D and Colquhoun A: The novel ruthenium-gamma-linolenic complex [Ru(2) (aGLA)(4)Cl] inhibits C6 rat glioma cell proliferation and induces changes in mitochondrial membrane potential, increased reactive oxygen species generation and apoptosis in vitro . Cell Biochem Funct 28(1): 15-23, 2010.
31. Grobben B, De Deyn PP and Slegers H: Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res 310(3): 257-270, 2002.
32. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN and Canoll P: Transplanted glioma cells migrate and proliferate on host brain vasculature: A dynamic analysis. Glia 53(8): 799-808, 2006.
33. Mazumder UK, Gupta M, Bhattacharya S, Karki SS, Rathinasamy S and Thangavel S: Antineoplastic and antibacterial activity of some mononuclear Ru(II) complexes. Enzyme Inhib Med Chem 19(2): 185-192, 2004a.
34. Mazumder UK, Gupta M, Karki SS, Bhattacharya S, Rathinasamy S and Thangavel S: Synthesis, anticancer and antibacterial activity of some novel mononuclear Ru(II) complexes. Chem Pharm Bull 52(2): 178-185, 2004b.
35. Zorzet S, Bergamo A, Cocchietto M, Sorc A, Gava B, Alessio E, Iengo E and Sava G: Lack of in vitro cytotoxicity, associated with increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo -selective antimetastasis activity of ruthenium complexes. J Pharmacol Exp Ther 295(3): 927-933, 2000.
36. Sava G, Frausin F, Cocchietto M, Vita F, Podda E, Spessotto P, Furlani A, Scarcia V and Zabucchi G: Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. Eur J Cancer 40(9): 1383-1396, 2004.
37. Sava G, Zorzet S, Turrin C, Vita F, Soranzo M, Zabucchi G, Cocchietto M, Bergamo A, DiGiovine S, Pezzoni G, Sartor L and Garbisa S: Dual Action of NAMI-A in inhibition of solid tumor metastasis: Selective targeting of metastatic cells and binding to collagen. Clin Cancer Res 9 (5): 1898-1905, 2003.
38. Gava B, Zorzet S, Spessotto P, Cocchietto M and Sava G: Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate and down-regulation of tumor cell invasion. Pharmacol Exp Ther 317(1): 284-291, 2006.
39. Sanna B, Debidda M, Pintus G, Tadolini B, Posadino AM, Bennardini F, Sava G and Ventura C: The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys 403(2): 209-218, 2002.
40. Pintus G, Tadolini B, Posadino AM, Sanna B, Debidda M, Bennardini F, Sava G and Ventura C: Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down-regulates c-MYC gene expression and endothelial cell proliferation. Eur J Biochem 269(23): 5861-5870, 2002.
41. Bergamo A and Sava G: Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans 13: 1267-1272, 2007.